Dan Skovronsky, Eli Lilly CSO
Eli Lilly adds $23B in market cap as investors rush on promise that this will be the amyloid Alzheimer's drug that works
It’s been decades and dozens of drugs, and most of them failed, but the amyloid hypothesis won’t go gently into the night.
While the world …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
